Sickle Cell Disease and Homoeopathy

Efficacy of Adjuvant Homoeopathic Treatment in Sickle Cell Disease - A Pilot, Single-Blind, Randomized, Placebo-Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087353

Enrollment

130

Registered

2025-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D57- Sickle-cell disorders

Interventions

Intervention1: Standard care with Individualized Homoeopathic medicine: Homoeopathic Medicines in compliance with pharmacopoeial standards from GMP compliant manufacturers would only be used. The medi

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patient of Sickle Cell Disease with reported episodes of acute vaso-occlusive crisis anytime in last 3 months Individuals with vaso occlusive crisis on day of enrollment will be enrolled after the episode of acute crisis is over.

Exclusion criteria

Exclusion criteria: Individuals having any severe complication of sickle cell disease like acute chest syndrome (ACS), aseptic necrosis of bone, etc. Individuals with any another hemolytic anemia such thalassemia, G6PD, hereditary spherocytosis, hemolytic uremic syndrome, etc. Individuals who have had bone marrow transplantation Individuals with self reported addictions to alcohol, severe end stage comorbidities like stroke, end stage kidney disease

Design outcomes

Primary

Measure	Time frame
Change in frequency, duration and intensity (FDI) of acute Vaso-occlusive pain crisis episodes Frequency will be measured as number of episodes each week Duration will be measured as number of days with pain severe enough to affect daily activities Intensity will be measured on VAS scale as the most severe pain occurring anytime during the acute episode Number of blood transfusions required during the follow up period Timepoint: Patient will be examined on monthly basis. The outcome will be assessed at baseline, 6 month, 12 months.	—

Measure

Time frame

Change in frequency, duration and intensity (FDI) of acute Vaso-occlusive pain crisis episodes Frequency will be measured as number of episodes each week Duration will be measured as number of days with pain severe enough to affect daily activities Intensity will be measured on VAS scale as the most severe pain occurring anytime during the acute episode Number of blood transfusions required during the follow up period Timepoint: Patient will be examined on monthly basis. The outcome will be assessed at baseline, 6 month, 12 months.

—

Secondary

Measure	Time frame
Change in hematological and biochemical parameters at 6 months and at 12 months as compared to baseline o Haemoglobin o TIBC (Total Iron Binding Capacity) o Red cell count o PCV (Packed Cell Volume) o MCV (Mean Corpuscular Volume) o MCH (Mean Corpuscular Haemoglobin) o MCHC (Mean Corpuscular Haemoglobin Concentration) o RDW (Red Cell Distribution Width) o Reticulocyte count o Serum ferritin o Serum iron o Vitamin B12 o Folic acid o Liver Function Test o Renal Function Test o Peripheral smear o Transferrin saturation percentage Number of days of missed work and loss of daily wages Assessment of quality of life based on Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) at baseline, 6 month and 12 months Timepoint: Patient will be examined on monthly basis. The outcome will be assessed at baseline, 6 month, 12 months.	—

Measure

Time frame

Change in hematological and biochemical parameters at 6 months and at 12 months as compared to baseline o Haemoglobin o TIBC (Total Iron Binding Capacity) o Red cell count o PCV (Packed Cell Volume) o MCV (Mean Corpuscular Volume) o MCH (Mean Corpuscular Haemoglobin) o MCHC (Mean Corpuscular Haemoglobin Concentration) o RDW (Red Cell Distribution Width) o Reticulocyte count o Serum ferritin o Serum iron o Vitamin B12 o Folic acid o Liver Function Test o Renal Function Test o Peripheral smear o Transferrin saturation percentage Number of days of missed work and loss of daily wages Assessment of quality of life based on Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) at baseline, 6 month and 12 months Timepoint: Patient will be examined on monthly basis. The outcome will be assessed at baseline, 6 month, 12 months.

—

Countries

India

Contacts

Public ContactDr Divya Taneja

Central Council for Research in Homoeopathy

renumittal8@gmail.com9717511115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026